AMD, XH, VK, AL, TL, LMM, NÖM, AS, and SKU declare no competing interests. The department of DB, MJ, BD, KH, and SM received funding from Chiesi Deutschland GmbH. DB received travel reimbursement from Chiesi. AFK received travel support, consulting fees and/or honoraria from Amicus, Biomarin, Chiesi, JCR Pharmaceuticals, Sanofi Genzyme, and Takeda. ML received travel support, consulting fees and/or honoraria from Amicus, Biomarin, Chiesi, JCR Pharmaceuticals, Sanofi Genzyme, and Takeda.
